Auris Medical (EARS) Announces Keyzilen Phase 3 Enrollment to Resume in Early 2017
Tweet Send to a Friend
Auris Medical Holding AG (Nasdaq: EARS) confirmed that the TACTT3 Phase 3 trial with Keyzilen (AM-101) will resume enrollment in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
